Oxidative stress in Parkinson's disease

Oxidative stress contributes to the cascade leading to dopamine cell degeneration in Parkinson's disease (PD). However, oxidative stress is intimately linked to other components of the degenerative process, such as mitochondrial dysfunction, excitotoxicity, nitric oxide toxicity and inflammation. It is therefore difficult to determine whether oxidative stress leads to, or is a consequence of, these events. Oxidative damage to lipids, proteins, and DNA occurs in PD, and toxic products of oxidative damage, such as 4‐hydroxynonenal (HNE), can react with proteins to impair cell viability. There is convincing evidence for the involvement of nitric oxide that reacts with superoxide to produce peroxynitrite and ultimately hydroxyl radical production. Recently, altered ubiquitination and degradation of proteins have been implicated as key to dopaminergic cell death in PD. Oxidative stress can impair these processes directly, and products of oxidative damage, such as HNE, can damage the 26S proteasome. Furthermore, impairment of proteasomal function leads to free radical generation and oxidative stress. Oxidative stress occurs in idiopathic PD and products of oxidative damage interfere with cellular function, but these form only part of a cascade, and it is not possible to separate them from other events involved in dopaminergic cell death. Ann Neurol 2003;53 (suppl 3):S26–S38

[1]  A. Schapira,et al.  Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal , 2004, Movement disorders : official journal of the Movement Disorder Society.

[2]  H. Hefter,et al.  Is levodopa toxic? , 2004, Journal of Neurology.

[3]  B. Halliwell,et al.  Proteasomal dysfunction induced by 4‐hydroxy‐2,3‐trans‐nonenal, an end‐product of lipid peroxidation: a mechanism contributing to neurodegeneration? , 2002, Journal of neurochemistry.

[4]  N. Hattori,et al.  Effect of Wild-type or Mutant Parkin on Oxidative Damage, Nitric Oxide, Antioxidant Defenses, and the Proteasome* , 2002, The Journal of Biological Chemistry.

[5]  B. Halliwell,et al.  The cytotoxicity of dopamine may be an artefact of cell culture , 2002, Journal of neurochemistry.

[6]  B. Halliwell,et al.  5‐S‐Cysteinyl‐conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase‐3 activity in neurons , 2002, Journal of neurochemistry.

[7]  P. Mander,et al.  Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration , 2002, Neuroscience.

[8]  S. Shin,et al.  Formation and Removal of α-Synuclein Aggregates in Cells Exposed to Mitochondrial Inhibitors* , 2002, The Journal of Biological Chemistry.

[9]  R. Swanson,et al.  Poly(ADP-ribose) glycohydrolase mediates oxidative and excitotoxic neuronal death , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Barry Halliwell,et al.  Failure of the ubiquitin–proteasome system in Parkinson's disease , 2001, Nature Reviews Neuroscience.

[11]  Moonhee Lee,et al.  Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production , 2001, Journal of neurochemistry.

[12]  R. Swanson,et al.  Astrocytes protect neurons from nitric oxide toxicity by a glutathione‐dependent mechanism , 2001, Journal of neurochemistry.

[13]  MoonHee Lee,et al.  Effect of the overexpression of wild‐type or mutant α‐synuclein on cell susceptibility to insult , 2001 .

[14]  K. McNaught,et al.  Proteasomal function is impaired in substantia nigra in Parkinson's disease , 2001, Neuroscience Letters.

[15]  K. O’Malley,et al.  The Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation , 2000, The Journal of Biological Chemistry.

[16]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[17]  N. Tatton Increased Caspase 3 and Bax Immunoreactivity Accompany Nuclear GAPDH Translocation and Neuronal Apoptosis in Parkinson's Disease , 2000, Experimental Neurology.

[18]  J. Trojanowski,et al.  Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. , 2000, The American journal of pathology.

[19]  K. McNaught,et al.  Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation. , 2000, Biochemical pharmacology.

[20]  C. Fall,et al.  Disrupted mitochondrial electron transport function increases expression of anti‐apoptotic Bcl‐2 and Bcl‐XL proteins in SH‐SY5Y neuroblastoma and in Parkinson disease cybrid cells through oxidative stress , 2000, Journal of neuroscience research.

[21]  E. Daikhin,et al.  Proteolytic degradation of tyrosine nitrated proteins. , 2000, Archives of biochemistry and biophysics.

[22]  R J Miller,et al.  The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. , 2000, Molecular pharmacology.

[23]  K. McNaught,et al.  Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release , 2000, Neuroscience Letters.

[24]  L. Shulman Levodopa toxicity in Parkinson disease: reality or myth? Reality--practice patterns should change. , 2000, Archives of neurology.

[25]  T. Miyata,et al.  4-hydroxynonenal induces a cellular redox status-related activation of the caspase cascade for apoptotic cell death. , 2000, Journal of cell science.

[26]  M. Mattson,et al.  The Lipid Peroxidation Product 4‐Hydroxy‐2,3‐Nonenal Increases AP‐1‐Binding Activity Through Caspase Activation in Neurons , 2000, Journal of neurochemistry.

[27]  S. Pennathur,et al.  Mass Spectrometric Quantification of 3-Nitrotyrosine, ortho-Tyrosine, and o,o′-Dityrosine in Brain Tissue of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Mice, a Model of Oxidative Stress in Parkinson's Disease* , 1999, The Journal of Biological Chemistry.

[28]  K. McNaught,et al.  Altered Glial Function Causes Neuronal Death and Increases Neuronal Susceptibility to 1‐Methyl‐4‐Phenylpyridinium‐ and 6‐Hydroxydopamine‐Induced Toxicity in Astrocytic/Ventral Mesencephalic Co‐Cultures , 1999, Journal of neurochemistry.

[29]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[30]  S. Shimohama,et al.  Depletion of Intracellular Glutathione Increases Susceptibility to Nitric Oxide in Mesencephalic Dopaminergic Neurons , 1999 .

[31]  Keiji Tanaka,et al.  4-Hydroxy-2-nonenal-mediated Impairment of Intracellular Proteolysis during Oxidative Stress , 1999, The Journal of Biological Chemistry.

[32]  D. Guastella,et al.  Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Montine,et al.  Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. , 1999, The American journal of pathology.

[34]  Paola Piccini,et al.  The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins , 1999, Annals of neurology.

[35]  T. Montine,et al.  4‐Hydroxy‐2(E)‐Nonenal Inhibits CNS Mitochondrial Respiration at Multiple Sites , 1999, Journal of neurochemistry.

[36]  M. Beal,et al.  Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase , 1999, Brain Research.

[37]  J. P. Henderson,et al.  8-Nitro-2'-deoxyguanosine, a specific marker of oxidation by reactive nitrogen species, is generated by the myeloperoxidase-hydrogen peroxide-nitrite system of activated human phagocytes. , 1999, Biochemistry.

[38]  T. Reinheckel,et al.  Comparative resistance of the 20S and 26S proteasome to oxidative stress. , 1998, The Biochemical journal.

[39]  A. Lees,et al.  Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species , 1998, Journal of neurochemistry.

[40]  A. Kingsbury,et al.  DNA fragmentation in human substantia nigra: Apoptosis or perimortem effect? , 1998, Movement disorders : official journal of the Movement Disorder Society.

[41]  H. Li,et al.  Brain Mitochondria Catalyze the Oxidation of 7‐(2‐Aminoethyl)‐3,4‐Dihydro‐5‐Hydroxy‐2H‐1,4‐Benzothiazine‐3‐Carboxylic Acid (DHBT‐1) to Intermediates that Irreversibly Inhibit Complex I and Scavenge Glutathione: Potential Relevance to the Pathogenesis of Parkinson's Disease , 1998, Journal of neurochemistry.

[42]  P. Damier,et al.  Glial cells and inflammation in parkinson's disease: A role in neurodegeneration? , 1998, Annals of neurology.

[43]  J. Obeso,et al.  Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection , 1998, Annals of neurology.

[44]  D. Perl,et al.  A fluorescent double‐labeling method to detect and confirm apoptotic nuclei in parkinson's disease , 1998, Annals of neurology.

[45]  M. Beal,et al.  Excitotoxicity and nitric oxide in parkinson's disease pathogenesis , 1998, Annals of neurology.

[46]  P. Jenner,et al.  Understanding cell death in parkinson's disease , 1998, Annals of neurology.

[47]  S. Shimohama,et al.  Dopamine D2‐type agonists protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stress , 1998, Annals of neurology.

[48]  E. Clementi,et al.  Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Cano,et al.  Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic System , 1998, Journal of neurochemistry.

[50]  D. Perl,et al.  Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.

[51]  J S Rakshi,et al.  Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET , 1998, Journal of neurology, neurosurgery, and psychiatry.

[52]  S. Daniel,et al.  Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[53]  E. Floor,et al.  Increased Protein Oxidation in Human Substantia Nigra Pars Compacta in Comparison with Basal Ganglia and Prefrontal Cortex Measured with an Improved Dinitrophenylhydrazine Assay , 1998, Journal of neurochemistry.

[54]  P. Leigh,et al.  Increased mitochondrial superoxide dismutase activity in Parkinson's disease but not amyotrophic lateral sclerosis motor cortex , 1997, Neuroscience Letters.

[55]  C. Fall,et al.  Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. , 1997, Biochimica et biophysica acta.

[56]  J. Blumberg,et al.  Regulation of Ubiquitin-conjugating Enzymes by Glutathione Following Oxidative Stress* , 1997, The Journal of Biological Chemistry.

[57]  S. Fahn Levodopa-Induced Neurotoxicity , 1997 .

[58]  V. Davila,et al.  Neurotrophic Effects of l‐DOPA in Postnatal Midbrain Dopamine Neuron/Cortical Astrocyte Cocultures , 1997, Journal of neurochemistry.

[59]  C D Marsden,et al.  Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.

[60]  K. Marder,et al.  Altered systemic iron metabolism in Parkinson's disease , 1997, Neurology.

[61]  A. Lees,et al.  A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease , 1997, Journal of neurochemistry.

[62]  J. Bennett,et al.  Mitochondrial toxins in models of neurodegenerative diseases. I: in vivo brain hydroxyl radical production during sytemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions , 1997, Brain Research.

[63]  J. Bennett,et al.  Mitochondrial toxins in models of neurodegenerative diseases. II: elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment , 1997, Brain Research.

[64]  P. Jenner,et al.  Nitric oxide synthase inhibition and MPTP‐induced toxicity in the common marmoset , 1997, Synapse.

[65]  J M Land,et al.  Nitric Oxide‐Mediated Mitochondrial Damage in the Brain: Mechanisms and Implications for Neurodegenerative Diseases , 1997, Journal of neurochemistry.

[66]  N. Hattori,et al.  An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease , 1997, Journal of the Neurological Sciences.

[67]  K. Hoyt,et al.  Mechanisms of Dopamine-Induced Cell Death in Cultured Rat Forebrain Neurons: Interactions with and Differences from Glutamate-Induced Cell Death , 1997, Experimental Neurology.

[68]  M. Graeber,et al.  On the question of apoptosis in the parkinsonian substantia nigra , 1997, Acta Neuropathologica.

[69]  A. Barzilai,et al.  Levodopa induces apoptosis in cultured neuronal cells—A possible accelerator of nigrostriatal degeneration in Parkinson's disease? , 1997, Movement disorders : official journal of the Movement Disorder Society.

[70]  Y. Goshima,et al.  Differential neurotoxicity induced by l-DOPA and dopamine in cultured striatal neurons , 1996, Brain Research.

[71]  R. Wyatt,et al.  Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. , 1996, Molecular pharmacology.

[72]  M. Beal,et al.  Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons , 1996, Nature Medicine.

[73]  F. Colpaert,et al.  Poly(ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice , 1996, Brain Research.

[74]  G. Dryhurst,et al.  Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. , 1996, Chemical research in toxicology.

[75]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Y. Agid,et al.  Nitric oxide synthase and neuronal vulnerability in parkinson's disease , 1996, Neuroscience.

[77]  Y. Mizuno,et al.  Histochemical detection of apoptosis in Parkinson's disease , 1996, Journal of the Neurological Sciences.

[78]  J. Bolaños,et al.  Depletion of brain glutathione results in a decrease of glutathione reductase activity; an enzyme susceptible to oxidative damage , 1996, Brain Research.

[79]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[80]  M. O’connor,et al.  DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[81]  S. K. Han,et al.  l‐DOPA Up‐Regulates Glutathione and Protects Mesencephalic Cultures Against Oxidative Stress , 1996, Journal of neurochemistry.

[82]  M. Mena,et al.  Glia conditioned medium protects fetal rat midbrain neurones in culture from L‐DOPA toxicity , 1996, Neuroreport.

[83]  J. Connor,et al.  A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains , 1995, Journal of neurochemistry.

[84]  B. Halliwell,et al.  Superoxide‐dependent depletion of reduced glutathione by L‐DOPA and dopamine. Relevance to Parkinson's disease , 1995, Neuroreport.

[85]  N. Hattori,et al.  Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. , 1995, Biochimica et biophysica acta.

[86]  C. Marsden,et al.  L‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain , 1995, Movement disorders : official journal of the Movement Disorder Society.

[87]  M. Youdim,et al.  Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. , 1995, European journal of pharmacology.

[88]  J. Schulz,et al.  Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.

[89]  Y. Glinka,et al.  Dopamine Neurotoxicity: Inhibition of Mitochondrial Respiration , 1995, Journal of neurochemistry.

[90]  C. Morris,et al.  Iron histochemistry of the substantia nigra in Parkinson's disease. , 1994, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[91]  C. Marsden,et al.  Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.

[92]  P. Jenner Oxidative damage in neurodegenerative disease , 1994, The Lancet.

[93]  S. Daniel,et al.  Glutathione‐related enzymes in brain in Parkinson's disease , 1994, Annals of neurology.

[94]  C. Marsden,et al.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.

[95]  F. Jiménez-Jiménez,et al.  Peripheral iron metabolism in patients with Parkinson's disease , 1994, Journal of the Neurological Sciences.

[96]  Kanefusa Kato,et al.  Cerebrospinal fluid levels of superoxide dismutases in neurological diseases detected by sensitive enzyme immunoassays , 1994, Journal of the Neurological Sciences.

[97]  Mitsutoshi Yamamoto,et al.  Differential effects of chronic l-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine , 1994, Neuroscience Letters.

[98]  C. Marsden,et al.  Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.

[99]  J. Cooper,et al.  Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease , 1993, Brain Research.

[100]  J. Coyle,et al.  Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.

[101]  C. Mytilineou,et al.  Toxic and Protective Effects of l‐DOPA on Mesencephalic Cell Cultures , 1993, Journal of neurochemistry.

[102]  P. Jenner,et al.  Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease , 1993, Acta neurologica Scandinavica. Supplementum.

[103]  E. Hirsch,et al.  Glutathione peroxidase, glial cells and Parkinson's disease , 1993, Neuroscience.

[104]  C. Marsden,et al.  New insights into the cause of Parkinson's disease , 1992, Neurology.

[105]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[106]  Barry Halliwell,et al.  Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.

[107]  C. W. Olanow,et al.  Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study , 1992, Brain Research.

[108]  K. Jellinger,et al.  Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease , 1992, Neuroscience Letters.

[109]  D. D. Di Monte,et al.  Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes. , 1992, Archives of biochemistry and biophysics.

[110]  C. Epstein,et al.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[111]  S. Markey,et al.  Search for neurotoxins structurally related to 1-methyl-4-phenylpyridine (MPP+) in the pathogenesis of Parkinson's disease , 1992, Brain Research.

[112]  J. Connor,et al.  A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains , 1992, Journal of neuroscience research.

[113]  P. Jenner Oxidative stress as a cause of Parkinson's disease , 1991, Acta neurologica Scandinavica. Supplementum.

[114]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[115]  P. Johannsen,et al.  Glutathione peroxidase in early and advanced Parkinson's disease. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[116]  S. Hirai,et al.  Dopa and dopamine cause cultured neuronal death in the presence of iron , 1991, Journal of the Neurological Sciences.

[117]  Y. Agid,et al.  Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.

[118]  D. Reif,et al.  Nitric oxide mediates iron release from ferritin. , 1990, Archives of biochemistry and biophysics.

[119]  K. Jellinger,et al.  Normal Mitochondrial Genome in Brain from Patients with Parkinson's Disease and Complex I Defect , 1990, Journal of neurochemistry.

[120]  Mazen Al-Hakim,et al.  Magnetic Resonance Imaging in Multiple Sclerosis , 1990, Neurology.

[121]  C. Marsden,et al.  Decreased Ferritin Levels in Brain in Parkinson's Disease , 1990, Journal of neurochemistry.

[122]  B. Freeman,et al.  Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[123]  P. Riederer,et al.  Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? , 1989, Acta neurologica Scandinavica. Supplementum.

[124]  Y. Kagawa,et al.  Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.

[125]  C. Marsden,et al.  A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.

[126]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[127]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[128]  E. Mukai,et al.  [Magnetic resonance imaging of parkinsonism]. , 1989, Rinsho shinkeigaku = Clinical neurology.

[129]  G. Ebers,et al.  Abnormalities in Iron Metabolism in Multiple Sclerosis , 1989, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[130]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[131]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[132]  G. Cohen,et al.  Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione. , 1988, The Journal of pharmacology and experimental therapeutics.

[133]  R. Marttila,et al.  Oxygen toxicity protecting enzymes in Parkinson's disease Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus , 1988, Journal of the Neurological Sciences.

[134]  S. Kish,et al.  Glutathione peroxidase activity in Parkinson's disease brain , 1985, Neuroscience Letters.

[135]  R. Clavier,et al.  Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l‐DOPA and Carbidopa Chronically , 1984, Journal of neurochemistry.

[136]  D. Godin,et al.  Parkinson's disease: A disorder due to nigral glutathione deficiency? , 1982, Neuroscience Letters.

[137]  R. Wurtman,et al.  Long‐term administration of L‐DOPA does not damage dopaminergic neurons in the mouse , 1981, Neurology.

[138]  D. Graham Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.

[139]  M. V. Van Woert,et al.  Brain peroxidase and catalase in Parkinson disease. , 1975, Archives of neurology.

[140]  G. Cohen,et al.  The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. , 1974, The Journal of biological chemistry.

[141]  R. Adams,et al.  6-Hydroxydopamine, a new oxidation mechanism. , 1972, European journal of pharmacology.

[142]  G. Reynolds,et al.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.

[143]  C. Marsden,et al.  Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease , 2005, Journal of Neural Transmission.

[144]  P. Mcgeer,et al.  Expression of the histocompatibility glycoprotein HLA-DR in neurological disease , 2004, Acta Neuropathologica.

[145]  B. Halliwell,et al.  Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys , 2002, Journal of Neural Transmission.

[146]  B. Halliwell,et al.  Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. , 2001, Journal of neurochemistry.

[147]  H. Li,et al.  Oxidative metabolites of 5-S-cysteinyldopamine inhibit the α-ketoglutarate dehydrogenase complex: possible relevance to the pathogenesis of Parkinson's disease , 2000, Journal of Neural Transmission.

[148]  D. Riley Is levodopa toxic to human substantia nigra? , 1998, Movement disorders : official journal of the Movement Disorder Society.

[149]  Y. Agid,et al.  Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. , 1997, Histology and histopathology.

[150]  J. Bolaños,et al.  Nitric oxide-mediated mitochondrial damage: a potential neuroprotective role for glutathione. , 1996, Free radical biology & medicine.

[151]  J. Greene,et al.  Bioenergetics and excitotoxicity: The weak excitotoxic hypothesis , 1996 .

[152]  N. Ogawa Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages. , 1994, European neurology.

[153]  C. Marsden,et al.  Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study , 1994, Movement disorders : official journal of the Movement Disorder Society.

[154]  P. Scheltens,et al.  Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[155]  T. Yoshikawa Free radicals and their scavengers in Parkinson's disease. , 1993, European neurology.

[156]  K. Mizukawa,et al.  Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. , 1993, Advances in neurology.

[157]  栄治 長谷川 1-methyl-4-phenylpyridinium (MPP[+]) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles , 1993 .

[158]  C. Marsden,et al.  Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease , 1992, Annals of neurology.

[159]  T. Chase,et al.  L‐dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria , 1991, Movement disorders : official journal of the Movement Disorder Society.

[160]  K. Jellinger,et al.  Brain iron and ferritin in Parkinson's and Alzheimer's diseases , 1990, Journal of neural transmission. Parkinson's disease and dementia section.

[161]  N. Quinn,et al.  Preservation of the substanitia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four‐year period , 1986, Movement disorders : official journal of the Movement Disorder Society.

[162]  D. Tse,et al.  Potential oxidative pathways of brain catecholamines. , 1976, Journal of medicinal chemistry.

[163]  K. Earle Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. , 1968, Journal of neuropathology and experimental neurology.

[164]  W. Gibb,et al.  Occasional Review , 2022 .